Search

Your search keyword '"Montefusco, V."' showing total 221 results
Start Over Author "Montefusco, V." Language english
221 results on '"Montefusco, V."'

3. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

Author

Gay, F, Oliva, S, Petrucci, M T, Montefusco, V, Conticello, C, Musto, P, Catalano, L, Evangelista, A, Spada, S, Campbell, P, Ria, R, Salvini, M, Offidani, M, Carella, A M, Omedé, P, Liberati, A M, Troia, R, Cafro, A M, Malfitano, A, Falcone, A P, Caravita, T, Patriarca, F, Nagler, A, Spencer, A, Hajek, R, Palumbo, A, and Boccadoro, M

Published
2017
Full Text
View/download PDF

4. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma

Author

Larocca, A, Bringhen, S, Petrucci, M T, Oliva, S, Falcone, A P, Caravita, T, Villani, O, Benevolo, G, Liberati, A M, Morabito, F, Montefusco, V, Passera, R, De Rosa, L, Omedé, P, Vincelli, I D, Spada, S, Carella, A M, Ponticelli, E, Derudas, D, Genuardi, M, Guglielmelli, T, Nozzoli, C, Aghemo, E, De Paoli, L, Conticello, C, Musolino, C, Offidani, M, Boccadoro, M, Sonneveld, P, and Palumbo, A

Published
2016
Full Text
View/download PDF

10. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

Author

Ziccheddu, B. Biancon, G. Bagnoli, F. De Philippis, C. Maura, F. Rustad, E.H. Dugo, M. Devecchi, A. De Cecco, L. Sensi, M. Terragna, C. Martello, M. Bagratuni, T. Kastritis, E. Dimopoulos, M.A. Cavo, M. Carniti, C. Montefusco, V. Corradini, P. Bolli, N.

Abstract

In multiple myeloma, novel treatments with proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs) have prolonged survival but the disease remains incurable. At relapse, next-generation sequencing has shown occasional mutations of drug targets but has failed to identify unifying features that underlie chemotherapy resistance. We studied 42 patients refractory to both PIs and IMiDs. Whole-exome sequencing was performed in 40 patients, and RNA sequencing (RNA-seq) was performed in 27. We found more mutations than were reported at diagnosis and more subclonal mutations, which implies ongoing evolution of the genome of myeloma cells during treatment. The mutational landscape was different from that described in published studies on samples taken at diagnosis. The TP53 pathway was the most frequently inactivated (in 45% of patients). Conversely, point mutations of genes associated with resistance to IMiDs were rare and were always subclonal. Refractory patients were uniquely characterized by having a mutational signature linked to exposure to alkylating agents, whose role in chemotherapy resistance and disease progression remains to be elucidated. RNA-seq analysis showed that treatment or mutations had no influence on clustering, which was instead influenced by karyotypic events. We describe a cluster with both amp(1q) and del(13) characterized by CCND2 upregulation and also overexpression of MCL1, which represents a novel target for experimental treatments. Overall, high-risk features were found in 65% of patients. However, only amp(1q) predicted survival. Gene mutations of IMiD and PI targets are not a preferred mode of drug resistance in myeloma. Chemotherapy resistance of the bulk tumor population is likely attained through differential, yet converging evolution of subclones that are overall variable from patient to patient and within the same patient. © 2020 by The American Society of Hematology.

Published
2020

11. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Author

Cavo, M. Gay, F. Beksac, M. Pantani, L. Petrucci, M.T. Dimopoulos, M.A. Dozza, L. van der Holt, B. Zweegman, S. Oliva, S. van der Velden, V.H.J. Zamagni, E. Palumbo, G.A. Patriarca, F. Montefusco, V. Galli, M. Maisnar, V. Gamberi, B. Hansson, M. Belotti, A. Pour, L. Ypma, P. Grasso, M. Croockewit, A. Ballanti, S. Offidani, M. Vincelli, I.D. Zambello, R. Liberati, A.M. Andersen, N.F. Broijl, A. Troia, R. Pascarella, A. Benevolo, G. Levin, M.-D. Bos, G. Ludwig, H. Aquino, S. Morelli, A.M. Wu, K.L. Boersma, R. Hajek, R. Durian, M. von dem Borne, P.A. Caravita di Toritto, T. Zander, T. Specchia, G. Waage, A. Gimsing, P. Mellqvist, U.-H. van Marwijk Kooy, M. Minnema, M. Mandigers, C. Cafro, A.M. Palmas, A. Carvalho, S. Spencer, A. Boccadoro, M. Sonneveld, P.

Abstract

Background: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib–melphalan–prednisone (VMP) as intensification therapy, and bortezomib–lenalidomide–dexamethasone (VRD) consolidation therapy with no consolidation. Methods: In this randomised, open-label, phase 3 study we recruited previously untreated patients with multiple myeloma at 172 academic and community practice centres of the European Myeloma Network. Eligible patients were aged 18–65 years, had symptomatic multiple myeloma stage 1–3 according to the International Staging System (ISS), measurable disease (serum M protein >10 g/L or urine M protein >200 mg in 24 h or abnormal free light chain [FLC] ratio with involved FLC >100 mg/L, or proven plasmacytoma by biopsy), and WHO performance status grade 0–2 (grade 3 was allowed if secondary to myeloma). Patients were first randomly assigned (1:1) to receive either four 42-day cycles of bortezomib (1·3 mg/m2 administered intravenously or subcutaneously on days 1, 4, 8, 11, 22, 25, 29, and 32) combined with melphalan (9 mg/m2 administered orally on days 1–4) and prednisone (60 mg/m2 administered orally on days 1–4) or autologous HSCT after high-dose melphalan (200 mg/m2), stratified by site and ISS disease stage. In centres with a double HSCT policy, the first randomisation (1:1:1) was to VMP or single or double HSCT. Afterwards, a second randomisation assigned patients to receive two 28-day cycles of consolidation therapy with bortezomib (1·3 mg/m2 either intravenously or subcutaneously on days 1, 4, 8, and 11), lenalidomide (25 mg orally on days 1–21), and dexamethasone (20 mg orally on days 1, 2, 4, 5, 8, 9, 11, and 12) or no consolidation; both groups received lenalidomide maintenance therapy (10 mg orally on days 1–21 of a 28-day cycle). The primary outcomes were progression-free survival from the first and second randomisations, analysed in the intention-to-treat population, which included all patients who underwent each randomisation. All patients who received at least one dose of study drugs were included in the safety analyses. This study is registered with the EU Clinical Trials Register (EudraCT 2009-017903-28) and ClinicalTrials.gov (NCT01208766), and has completed recruitment. Findings: Between Feb 25, 2011, and April 3, 2014, 1503 patients were enrolled. 1197 patients were eligible for the first randomisation, of whom 702 were assigned to autologous HSCT and 495 to VMP; 877 patients who were eligible for the first randomisation underwent the second randomisation to VRD consolidation (n=449) or no consolidation (n=428). The data cutoff date for the current analysis was Nov 26, 2018. At a median follow-up of 60·3 months (IQR 52·2–67·6), median progression-free survival was significantly improved with autologous HSCT compared with VMP (56·7 months [95% CI 49·3–64·5] vs 41·9 months [37·5–46·9]; hazard ratio [HR] 0·73, 0·62–0·85; p=0·0001). For the second randomisation, the number of events of progression or death at data cutoff was lower than that preplanned for the final analysis; therefore, the results from the second protocol-specified interim analysis, when 66% of events were reached, are reported (data cutoff Jan 18, 2018). At a median follow-up of 42·1 months (IQR 32·3–49·2), consolidation therapy with VRD significantly improved median progression-free survival compared with no consolidation (58·9 months [54·0–not estimable] vs 45·5 months [39·5–58·4]; HR 0·77, 0·63–0·95; p=0·014). The most common grade ≥3 adverse events in the autologous HSCT group compared to the VMP group included neutropenia (513 [79%] of 652 patients vs 137 [29%] of 472 patients), thrombocytopenia (541 [83%] vs 74 [16%]), gastrointestinal disorders (80 [12%] vs 25 [5%]), and infections (192 [30%] vs 18 [4%]). 239 (34%) of 702 patients in the autologous HSCT group and 135 (27%) of 495 in the VMP group had at least one serious adverse event. Infection was the most common serious adverse event in each of the treatment groups (206 [56%] of 368 and 70 [37%] of 189). 38 (12%) of 311 deaths from first randomisation were likely to be treatment related: 26 (68%) in the autologous HSCT group and 12 (32%) in the VMP group, most frequently due to infections (eight [21%]), cardiac events (six [16%]), and second primary malignancies (20 [53%]). Interpretation: This study supports the use of autologous HSCT as intensification therapy and the use of consolidation therapy in patients with newly diagnosed multiple myeloma, even in the era of novel agents. The role of high-dose chemotherapy needs to be reassessed in future studies, in particular in patients with undetectable minimal residual disease after four-drug induction regimens including a monoclonal antiboby combined with an immunomodulatory agent and a proteasome inhibitor plus dexamethasone. Funding: Janssen and Celgene. © 2020 Elsevier Ltd

Published
2020

20. Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample o outpatients with schizophrenia and their unaffected relatives

Author

Mucci A., Galderisi S., Green M. F., Nuechterlein K., Rucci P., Gibertoni D., Rossi A., Rocca P., Bertolino A., Bucci P., Hellemann G., Spisto M., Palumbo D., Aguglia E., Amodeo G., Amore M., Bellomo A., Brugnoli R., Carpiniello B., Dell'osso L., Di Fabio F., Di Giannantonio M., Di Lorenzo G., Marchesi C., Monteleone P., Montemagni C., Oldani L., Romano R., Roncone R., Stratta P., Tenconi E., Vita A., Zeppegno P., Maj M., Piegari G., Vignapiano A., Caputo F., Plescia G., Montefusco V., Mancini M., Attrotto M. T., Paladini V., Atti A. R., Barlati S., Galluzzo A., Mussoni C., Pinna F., Sanna L., Primavera D., Signorelli M. S., Minutolo G., Cannavo D., Acciavatti T., Santacroce R., Corbo M., Altamura M., La Montagna M., Carnevale R., Pizziconi G., Rossi R., Santarelli V., Giusti L., Malavolta M., Salza A., Murri M. B., Calcagno P., Bugliani M., Serati M., Orsenigo G., Gramaglia C., Gattoni E., Cattaneo C., Campagnola N., Ferronato L., Piovan C., Tonna M., Bettini E., Ossola P., Gesi C., Landi P., Rutigliano G., Biondi M., Girardi P., Buzzanca A., Zocconali M., Comparelli A., Mancinelli I., Niolu C., Ribolsi M., Siracusano A., Corrivetti G., Bartoli L., Diasco F., Bolognesi S., Goracci A., Fagiolini A., Bellino S., Cardillo S., Bracale N., Mucci, A., Galderisi, S., Green, M. F., Nuechterlein, K., Rucci, P., Gibertoni, D., Rossi, A., Rocca, P., Bertolino, A., Bucci, P., Hellemann, G., Spisto, M., Palumbo, D., Aguglia, E., Amodeo, G., Amore, M., Bellomo, A., Brugnoli, R., Carpiniello, B., Dell'Osso, L., Di Fabio, F., Di Giannantonio, M., Di Lorenzo, G., Marchesi, C., Monteleone, P., Montemagni, C., Oldani, L., Romano, R., Roncone, R., Stratta, P., Tenconi, E., Vita, A., Zeppegno, P., Maj, M., Piegari, G., Vignapiano, A., Caputo, F., Plescia, G., Montefusco, V., Mancini, M., Attrotto, M. T., Paladini, V., Atti, A. R., Barlati, S., Galluzzo, A., Mussoni, C., Pinna, F., Sanna, L., Primavera, D., Signorelli, M. S., Minutolo, G., Cannavo, D., Acciavatti, T., Santacroce, R., Corbo, M., Altamura, M., La Montagna, M., Carnevale, R., Pizziconi, G., Rossi, R., Santarelli, V., Giusti, L., Malavolta, M., Salza, A., Murri, M. B., Calcagno, P., Bugliani, M., Serati, M., Orsenigo, G., Gramaglia, C., Gattoni, E., Cattaneo, C., Campagnola, N., Ferronato, L., Piovan, C., Tonna, M., Bettini, E., Ossola, P., Gesi, C., Landi, P., Rutigliano, G., Biondi, M., Girardi, P., Buzzanca, A., Zocconali, M., Comparelli, A., Mancinelli, I., Niolu, C., Ribolsi, M., Siracusano, A., Corrivetti, G., Bartoli, L., Diasco, F., Bolognesi, S., Goracci, A., Fagiolini, A., Bellino, S., Cardillo, S., Bracale, N., and di Giannantonio, M.

Subjects
Attention, MCCB Italian standardization, reasoning and problem solving, social cognition, verbal learning, working memory, Proband, Adult, Male, Consensus, Psychometrics, Context (language use), social cognition, Verbal learning, working memory, 03 medical and health sciences, Attention, MCCB Italian standardization, reasoning and problem solving, verbal learning, Aged, Cognition, Cognitive Dysfunction, Family, Female, Humans, Middle Aged, Outpatients, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, 0302 clinical medicine, Social cognition, medicine, Applied Psychology, Psychiatry and Mental Health, Family aggregation, medicine.disease, 030227 psychiatry, Settore MED/25, Psychology, MATRICS, Neurocognitive, 030217 neurology & neurosurgery, Clinical psychology
Abstract

BackgroundThe increased use of the MATRICS Consensus Cognitive Battery (MCCB) to investigate cognitive dysfunctions in schizophrenia fostered interest in its sensitivity in the context of family studies. As various measures of the same cognitive domains may have different power to distinguish between unaffected relatives of patients and controls, the relative sensitivity of MCCB tests for relative–control differences has to be established. We compared MCCB scores of 852 outpatients with schizophrenia (SCZ) with those of 342 unaffected relatives (REL) and a normative Italian sample of 774 healthy subjects (HCS). We examined familial aggregation of cognitive impairment by investigating within-family prediction of MCCB scores based on probands’ scores.MethodsMultivariate analysis of variance was used to analyze group differences in adjusted MCCB scores. Weighted least-squares analysis was used to investigate whether probands’ MCCB scores predicted REL neurocognitive performance.ResultsSCZ were significantly impaired on all MCCB domains. REL had intermediate scores between SCZ and HCS, showing a similar pattern of impairment, except for social cognition. Proband's scores significantly predicted REL MCCB scores on all domains except for visual learning.ConclusionsIn a large sample of stable patients with schizophrenia, living in the community, and in their unaffected relatives, MCCB demonstrated sensitivity to cognitive deficits in both groups. Our findings of significant within-family prediction of MCCB scores might reflect disease-related genetic or environmental factors.

Published
2018

22. Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM: A451

Author

Cavo, M, Zambello, R, Nozzoli, C, Gugliotta, L, Pantani, L, Patriarca, F, Petrucci, M T, Tacchetti, P, Galli, M, Ceccolini, M, Di Raimondo, F, Rossi, G, Zamagni, E, Bringhen, S, Narni, F, Tosi, P, Montefusco, V, Offidani, M, Brioli, A, Pallotti, M C, Spadano, T, Pescosta, N, Goldaniga, M, Ledda, A, Perrone, G, Petrucci, A, Caravita, T, Cascavilla, N, Gherlinzoni, F, De Stefano, V, Angelucci, E, Petti, M C, Ballanti, S, Callea, V, and Baccarani, M

Published
2009

28. Disorganization and cognitive impairment in schizophrenia: new insights from electrophysiological findings

Author

Vignapiano, A., Koenig, T., Mucci, A., Giordano, G. M., Amodio, A., Altamura, M., Bellomo, A., Brugnoli, R., Corrivetti, G., Di Lorenzo, G., Girardi, P., Monteleone, P., Niolu, C., Galderisi, S., Maj, M., Piegari, G., Merlotti, E., Plescia, G. M., Montefusco, V., Gallo, O., Romano, P., Carnevale, R., La Montagna, M., Ferrentino, F., Siracusano, A., Comparelli, A., Corigliano, V., Cascino, G., Del Buono, G., Vignapiano, A., Koenig, T., Mucci, A., Giordano, G. M., Amodio, A., Altamura, M., Bellomo, A., Brugnoli, R., Corrivetti, G., Di Lorenzo, G., Girardi, P., Monteleone, P., Niolu, C., Galderisi, S., and Maj, M.

Subjects
Adult, Male, medicine.medical_specialty, alpha rhythm, difficulty in abstract thinking, disorganization dimension, neurocognitive domains, spectral power, topographic analysis, Alpha (ethology), Audiology, Neuropsychological Tests, 050105 experimental psychology, Correlation, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Cognition, Physiology (medical), medicine, Humans, 0501 psychology and cognitive sciences, Cognitive Dysfunction, 610 Medicine & health, Association (psychology), Problem Solving, Positive and Negative Syndrome Scale, General Neuroscience, 05 social sciences, Brain, Electroencephalography, 500 Science, Middle Aged, medicine.disease, Brain Waves, Electrophysiology, Neuropsychology and Physiological Psychology, Settore MED/25, Schizophrenia, 570 Life sciences, biology, Neurocognitive domain, Female, Schizophrenic Psychology, Psychology, Neurocognitive, 030217 neurology & neurosurgery
Abstract

In subjects with schizophrenia (SCZ), the disorganization dimension is a strong predictor of real-life functioning. "Conceptual disorganization" (P2), "Difficulty in abstract thinking" (N5) and "Poor attention" (G11) are core features of the disorganization factor, evaluated using the Positive and Negative Syndrome Scale. The heterogeneity of this dimension and its overlap with neurocognitive deficits are still debated. Within the multicenter study of the Italian Network for Research on Psychoses, we investigated electrophysiological and neurocognitive correlates of disorganization and its component items to assess the heterogeneity of this dimension and its possible overlap with neurocognitive deficits. Resting state EEG was recorded in 145 stabilized SCZ and 69 matched healthy controls (HC). Spectral amplitude was averaged in ten frequency bands. Neurocognitive domains were assessed by MATRICS Consensus Cognitive Battery (MCCB). RAndomization Graphical User software explored band spectral amplitude differences between groups and correlations with disorganization and MCCB scores in SCZ. Correlations between disorganization and MCCB scores were also investigated. Compared to HC, SCZ showed increased delta, theta, and beta 1 and decreased alpha 2 activity. A negative correlation between alpha 1 and disorganization was observed in SCZ. At the item level, only "N5" showed the same correlation. MCCB neurocognitive composite score was associated with disorganization, "P2" and "N5". Our findings suggest only a partial overlap between disorganization and neurocognitive impairment. The association of alpha 1 with the "N5" item suggests that some aspects of disorganization could be underpinned by the impairment of basic neurobiological functions that are only partially evaluated using MCCB.

Published
2019

31. Tandem auto-miniALLO approach for newly diagnosed multiple myeloma: an update of the Italian experience

Author

Bruno, B., Patriarca, F., Rotta, M., Maloney, D., Mordini, N., Casini, M., Rambaldi, A., Carnevale-Schianca, F., Allione, B., Soligo, D., Bavaro, P., Giaccone, L., Sorsasio, R., Montefusco, V., Busca, A., Fanin, R., Gallamini, A., Coser, P., Corradini, P., Levis, A., Aglietta, M., Pogliani, E., Falda, M., Massaia, M., Palumbo, A., Sandmaier, B., Storb, R., and Boccadoro, M.

Published
2005

33. Social cognition in people with schizophrenia: a cluster-analytic approach

Author

Rocca, P., Galderisi, S., Rossi, A., Bertolino, A., Rucci, P., Gibertoni, D., Montemagni, C., Sigaudo, M., Mucci, A., Bucci, P., Acciavatti, T., Aguglia, E., Amore, M., Bellomo, A., Deronchi, D., Osso, L., Difabio, F., Girardi, P., Goracci, A., Marchesi, C., Monteleone, P., Niolu, C., Pinna, F., Roncone, R., EMILIO SACCHETTI, Santonastaso, P., Zeppegno, P., Maj, M., Chieffi, M., Piegari, M., Vignapiano, A., Merlotti, E., Plescia, G., Montefusco, V., Bava, I., Mancini, I., Sandei, L., Antoniettanettis, I., Rizzo, G., Mancini, M., Porcelli, S., Salfi, G., Bianchini, O., Antonio Vita, Galluzzo, G., Barlati, S., Carpiniello, B., Primavera, D., Floris, S., Salvina, Signorelli, Minutolo, B., Cannavò, G., Corbo, D., Vellante, M., Alessandrini, F., Poli, M., Altamura, M., Petito, M., Marasco, A., Vaggi, D., Calcagno, M., Marozzi, P., Ussorio, V., Giusti, D., Malavolta, L., Diemidio, M., Stratta, G., Collazzoni, P., Debartolomeis, P., Gramaglia, P., Gili, C., Gattoni, S., Ferronato, E., Giannunzio, L., Tenconi, V., Tonna, E., Ossola, M., Camerlengo, P., Landi, E., Rutigliano, P., Buzzanca, G., Paolemili, A., Frascarelli, M., Comparelli, M., Corigliano, A., Brugnoli, V., Siracusano, R., Troisi, A., Dilorenzo, A., Filippo, Di, Longobardi, C., Castaldo, N., Fagiolini, E., Bolognesi, A., Capua, De, A, DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE, Facolta' di MEDICINA e CHIRURGIA, AREA MIN. 06 - Scienze mediche, Da definire, Rocca, P, Galderisi, S., Rossi, A., Bertolino, A., Rucci, P., Gibertoni, D., Montemagni, C., Sigaudo, M., Mucci, A., Bucci, P., Acciavatti, T., Aguglia, E., Amore, M., Bellomo, A., De Ronchi, D., Dell'Osso, L., Di Fabio, F., Girardi, P., Goracci, A., Marchesi, C., Monteleone, P., Niolu, C., Pinna, F., Roncone, R., Sacchetti, E., Santonastaso, P., Zeppegno, P., Maj, M., Rocca, P., Chieffi, M., Piegari, M., Vignapiano, A., Merlotti, E., Plescia, G., Montefusco, V., Bava, I., Mancini, I., Sandei, L., Antonietta Nettis, I., Rizzo, G., Mancini, M., Porcelli, S., Salfi, G., Bianchini, O., Vita, A., Galluzzo, G., Barlati, S., Carpiniello, B., Primavera, D., Floris, S., Salvina Signorelli, B., Minutolo, G., Cannavo, D., Corbo, M., Vellante, F., Alessandrini, M., Poli, M., Altamura, M., Petito, A., Marasco, D., Vaggi, M., Calcagno, P., Marozzi, V., Ussorio, D., Giusti, L., Malavolta, M., Di Emidio, G., Stratta, P., Collazzoni, P., De Bartolomeis, P., Gramaglia, C., Gili, S., Gattoni, E., Ferronato, L., Giannunzio, V., Tenconi, E., Tonna, M., Ossola, P., Camerlengo, E., Landi, P., Rutigliano, G., Buzzanca, A., Paolemili, M., Frascarelli, M., Comparelli, A., Corigliano, V., Brugnoli, R., Siracusano, A., Troisi, A., Di Lorenzo, G., Di Filippo, C., Longobardi, N., Castaldo, E., Fagiolini, A., Bolognesi, S., De Capua, A., and Italian Network for Research on, Psychoses

Subjects
Adult, Male, Context (language use), social cognition, Italian Network for Research on Psychoses, 03 medical and health sciences, 0302 clinical medicine, Cluster analysis, Social cognition, Emotion perception, medicine, schizophrenia, theory of mind, Cluster Analysis, Emotional Intelligence, Facial Recognition, Female, Humans, Middle Aged, Schizophrenia, Facial Expression, Social Perception, Wit and Humor as Topic, Applied Psychology, Psychiatry and Mental Health, Cluster analysis Italian Network for Research on Psychosesschizophrenia social cognition theory of mind, Cluster analysi, Italian Network for Research on Psychose, Settore MED/25 - Psichiatria, Facial expression, Social perception, Emotional intelligence, medicine.disease, cluster analysis, italian network for research on psychoses, adult, emotional intelligence, facial recognition, female, humans, male, middle aged, facial expression, social perception, wit and humor as topic, applied psychology, psychiatry and mental health, 030227 psychiatry, Psychology, Neurocognitive, 030217 neurology & neurosurgery, Clinical psychology
Abstract

none 28 no BACKGROUND: The study aimed to subtype patients with schizophrenia on the basis of social cognition (SC), and to identify cut-offs that best discriminate among subtypes in 809 out-patients recruited in the context of the Italian Network for Research on Psychoses. METHOD: A two-step cluster analysis of The Awareness of Social Inference Test (TASIT), the Facial Emotion Identification Test and Mayer-Salovey-Caruso Emotional Intelligence Test scores was performed. Classification and regression tree analysis was used to identify the cut-offs of variables that best discriminated among clusters. RESULTS: We identified three clusters, characterized by unimpaired (42%), impaired (50.4%) and very impaired (7.5%) SC. Three theory-of-mind domains were more important for the cluster definition as compared with emotion perception and emotional intelligence. Patients more able to understand simple sarcasm (⩾14 for TASIT-SS) were very likely to belong to the unimpaired SC cluster. Compared with patients in the impaired SC cluster, those in the very impaired SC cluster performed significantly worse in lie scenes (TASIT-LI

Published
2016

36. PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (VPD) AS INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA CANDIDATES TO AUTOLOGOUS TRANSPLANT

Author

Mangiacavalli, S., Montefusco, V., Pochintesta, L., Baldini, L., Virginia Valeria Ferretti, Farina, L., Cocito, F., Ravelli, E., La Targia, M. L., Cairoli, R., Corso, A., Mangiacavalli, S, Montefusco, V, Pochintesta, L, Baldini, L, Ferretti, V, Farina, L, Cocito, F, Ravelli, E, La Targia, M, Cairoli, R, and Corso, A

Subjects
hepatology
Published
2014

38. Relazione fra la forma urbana e i luoghi dell’alimentazione: dal rilievo manuale all'optioneering. Seconda parte: I luoghi dell’alimentazione e i percorsi a vocazione artistico monumentale: optioneering e valutazione parametrica

Author

De Paoli, M., Capone, A., Montefusco, V., and Segolini, M.

Subjects
optioneering, applicazioni mobile, smart city, parametric tool, luoghi di interesse alimentare e turistico, smart city. optioneering, optioneering, strumento parametrico, luoghi di interesse alimentare e turistico, applicazioni mobile, smart city. optioneering, parametric tool, nutrition and tourist space, mobile applications, smart city, strumento parametrico, nutrition and tourist space, mobile applications
Published
2015

39. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio COLLABORATORI: Tosi, P, Motta, Mr, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, Franco, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, Mc, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, Am, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, Mc, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E., Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A., Cavo, Michele, Pantani, Lucia, Petrucci, Maria Teresa, Patriarca, Francesca, Zamagni, Elena, Donnarumma, Daniela, Crippa, Claudia, Boccadoro, Mario, Perrone, Giulia, Falcone, Antonietta, Nozzoli, Chiara, Zambello, Renato, Masini, Luciano, Furlan, Anna, Brioli, Annamaria, Derudas, Daniele, Ballanti, Stelvio, Dessanti, Maria Laura, De Stefano, Valerio, Carella, Angelo Michele, Marcatti, Magda, Nozza, Andrea, Ferrara, Felicetto, Callea, Vincenzo, Califano, Catello, Pezzi, Annalisa, Baraldi, Anna, Grasso, Mariella, Musto, Pellegrino, Palumbo, Antonio, Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, and Quartarone, E

Subjects
Male, Boronic Acid, medicine.medical_treatment, PLUS DEXAMETHASONE, Phases of clinical research, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, Biochemistry, Antineoplastic Agent, Bortezomib-thalidomide-dexamethasone, Bortezomib, Immunosuppressive Agent, Autologous stem-cell transplantation, MULTIPLE MYELOMA, Antineoplastic Combined Chemotherapy Protocols, thalidomide-dexamethasone, Multiple myeloma, RANDOMIZED PHASE-3, LENALIDOMIDE, STEM CELL TRANSPLANTATION, Hematopoietic Stem Cell Transplantation, PHASE-III TRIAL, Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, Boronic Acids, Combined Modality Therapy, Thalidomide, Transplantation, Autologou, Pyrazines, HIGH-DOSE MELPHALAN, INDUCTION TREATMENT, Female, Autologous, Immunosuppressive Agents, Pyrazine, Human, medicine.drug, MAINTENANCE THERAPY, medicine.medical_specialty, DOXORUBICIN, Antineoplastic Agents, Hormonal, Prognosi, Immunology, Urology, Antineoplastic Agents, dexamethasone, Transplantation, Autologous, Disease-Free Survival, Dexamethasone, Humans, Multiple Myeloma, Cell Biology, medicine, Autologous transplantation, METAANALYSIS, Transplantation, Antineoplastic Combined Chemotherapy Protocol, Hormonal, business.industry, medicine.disease, Surgery, business, Settore MED/15 - Malattie del Sangue
Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

42. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment

Author

Morabito, F, Gentile, M, Mazzone, C, Rossi, D, Di Raimondo, F, Bringhen, S, Ria, R, Offidani, M, Patriarca, F, Nozzoli, C, Petrucci, Mt, Benevolo, G, Vincelli, I, Guglielmelli, T, Grasso, M, Marasca, R, Baldini, L, Montefusco, V, Musto, P, Cascavilla, N, Majolino, I, Musolino, Caterina, Cavo, M, Boccadoro, M, Palumbo, A, Musolino, C., Morabito F., Gentile M., Mazzone C., Rossi D., Di Raimondo F., Bringhen S., Ria R., Offidani M., Patriarca F., Nozzoli C., Petrucci M.T., Benevolo G., Vincelli I., Guglielmelli T., Grasso M., Marasca R., Baldini L., Montefusco V., Musto P., Cascavilla N., Majolino I., Musolino C., Cavo M., Boccadoro M., and Palumbo A.

Subjects
Melphalan, Male, CHRONIC KIDNEY-DISEASE, DOXORUBICIN-DEXAMETHASONE BDD, PRESENTING FEATURES, FAILURE ARF, PHASE-II, REGIMENS, REVERSIBILITY, PATHOGENESIS, REVERSAL, SURVIVAL, Biochemistry, Bortezomib, chemistry.chemical_compound, MULTIPLE MYELOMA, Prednisone, Multiple myeloma, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma, thalidomide, bortezomib-melphalan-prednisone, Kidney, treatment, Hematology, Induction Chemotherapy, Boronic Acids, Neoadjuvant Therapy, Thalidomide, medicine.anatomical_structure, Treatment Outcome, Pyrazines, Female, Kidney Diseases, medicine.drug, Glomerular Filtration Rate, renal impairment, medicine.medical_specialty, Immunology, Urology, Renal function, MPT-VT, Maintenance Chemotherapy, medicine, Humans, Adverse effect, Aged, Creatinine, business.industry, Cell Biology, medicine.disease, Survival Analysis, Surgery, melphalan, chemistry, VMP, prednisone, bortezomib-melphalan-prednisone-thalidomide, business
Abstract

We assessed efficacy, safety, and reversal of renal impairment (RI) in untreated patients with multiple myeloma given bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance or bortezomib-melphalan-prednisone (VMP). Exclusion criteria included serum creatinine ≥ 2.5 mg/dL. In the VMPT-VT/VMP arms, severe RI (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min), moderate RI (eGFR 31-50 mL/min), and normal renal function (eGFR > 50 mL/min), were 6%/7.9%, 24.1%/24.9%, and 69.8%/67.2%, respectively. Statistically significant improvements in overall response rates and progression-free survival were observed in VMPT-VT versus VMP arms across renal cohorts, except in severe RI patients. In the VMPT group, severe RI reduced overall survival (OS). RI was reversed in 16/63 (25.4%) patients receiving VMPT-VT versus 31/77 (40.3%) receiving VMP. Multivariate analysis showed male sex (P = .022) and moderate RI (P = .003) significantly predicted RI recovery. VMP patients achieving renal response showed longer OS. In both arms, greater rates of severe hematologic adverse events were associated with RI (eGFR < 50 mL/min), however, therapy discontinuation rates were unaffected. VMPT-VT was superior to VMP for cases with normal renal function and moderate RI, whereas VMPT-VT failed to outperform VMP in patients with severe RI, although the relatively low number of cases analyzed preclude drawing definitive conclusions. VMPT-VT had no advantage in terms of RI reversal over VMP. This study is registered at http://www.clinicaltrials.gov as NCT01063179.

Published
2011

44. Long-term outcome of ric-allo SCT for myeloma

Author

Montefusco V, CICERI , FABIO, Peccatori J, Farina L, Olivieri A, Hoenstaufen K, Deliliers GL, Gianni AM, Bregni M, Corradini P., Montefusco, V, Ciceri, Fabio, Peccatori, J, Farina, L, Olivieri, A, Hoenstaufen, K, Deliliers, Gl, Gianni, Am, Bregni, M, and Corradini, P.

Subjects
Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
2007

45. SUBCUTANEOUS VELCADE PLUS PREDNISONE (VP) OR PLUS CYCLOPHOSFAMIDE (VCP) OR PLUS MELPHALAN (VMP) IN FRAIL, ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A PHASE II COMMUNITY–BASED STUDY

Author

Larocca, A, Oliva, S, Offidani, M, Levi, A, Musolino, Caterina, Falcone, Ap, Conticello, C, Caravita, T, Rossi, D, Villani, O, Nozzoli, C, Benevolo, G, Liberati, Am, Morabito F, Derudas D., Carella, Am, Caraffa, P, Astolfi, M, Palladino, C, Montefusco, V, Cavallo, F, Petrucci, Mt, Boccadoro, M, Sonneveld, P, and Palumbo, A.

Subjects
subcutaneous bortezomib, Multiple Myeloma, subcutaneous bortezomib, Multiple Myeloma
Published
2013

47. Efficacy and safety of 3 lenalidomide–based combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based EMN01 trial

Author

Gay, F, Bringhen, S, Offidani, M, Liberati, Am, Cellini, C, Magarotto, V, Benevolo, G, Aitoro, G, Patriarca, F, Omede, P, Conticello, C, Montefusco, V, Rossi, D, Palladino, C, Pour, L, Allegra, Alessandro, Pietrantuono, G, Falcone, Ap, Rocci, A, Zambello, R, Ledda, A, Gentili, S, Musto, P, Boccadoro, M, Hajek, R, and Palumbo, A.

Subjects
Multiple myeloma, Lenalidomide, EMN01, EMN01, Multiple myeloma, Lenalidomide
Published
2013

48. IMPACT OF UPFRONT BORTEZOMIB-BASED REGIMENS ON CLINICAL OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACCORDING TO CYTOGENETIC ABNORMALITIES BY FISH ANALYSIS

Author

Cavo, M., Palumbo, A., Bringhen, S., DI RAIMONDO, Francesco, Patriarca, F., Rossi, D., Levi, A., Offidani, M., Montefusco, V., Narni, F., Zambello, R., Benevolo, G., Grasso, M., Falcone, A., Musto, P., Guglielmelli, T., Gherlinzoni, F., Gottardi, D., Musolino, C., DI RENZO, N., Masini, L., Cangialosi, C., Dore, F., Ballanti, S., Storti, S., Angelucci, E., Vallone, R., Magarotto, V., Morabito, F., Tosi, P., and Boccadoro, M.

Published
2010

49. ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS

Author

Gay, F., Larocca, A., Petrucci, Mt, Musto, P., Liberati, Am, Callea, V., Ria, R., Caravita, T., Cangialosi, C., Grasso, M., Offidani, M., Pregno, P., Patriarca, F., Galli, M., Cavo, M., Catalano, L., Nozzoli, C., Guglielmelli, T., Zambello, R., Pisani, F., Montefusco, V., Rossini, F., DE STEFANO, V., Lupo, B., DI RAIMONDO, Francesco, Gaidano, G., Boccadoro, M., and Palumbo, A.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results